Myeloproliferative Neoplasm, BCR-ABL1 Negative

Myeloproliferative Neoplasm, BCR-ABL1 Negative — Trials · CancerIndex

Clinical trials

Registered studies

333 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 94
Recruiting: 50
Ph III recruiting: 7
Growth YoY: —
Industry share: 41%
Top sponsor: City of Hope Medical Center
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–50 of 70 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00081874	RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma	completed	Phase 1 / Phase 2	29	M.D. Anderson Cancer CenterOTHER	1	Jun 18, 2026	clinicaltrials
NCT02158858	A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies	completed	Phase 1 / Phase 2	336	Constellation PharmaceuticalsINDUSTRY	9	Jun 4, 2026